Aligos Therapeutics
Clinical trials sponsored by Aligos Therapeutics, explained in plain language.
-
New hepatitis b drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new daily pill, ALG-000184, against a standard hepatitis B drug (tenofovir) in 200 adults with chronic hepatitis B. The goal is to see if the new drug can better lower the amount of virus in the blood after 48 weeks. Participants must have untreated hepatitis B…
Phase: PHASE2 • Sponsor: Aligos Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:43 UTC
-
New hepatitis b drug tested in kidney patients
Knowledge-focused Recruiting nowThis early-stage study looks at how the body processes a single dose of pevifoscorvir sodium (ALG-000184) in people with chronic hepatitis B who have different levels of kidney function. About 30 adults with severe, mild, moderate, or no kidney impairment will take part. The goal…
Phase: PHASE1 • Sponsor: Aligos Therapeutics • Aim: Knowledge-focused
Last updated May 26, 2026 05:55 UTC
-
New hepatitis b drug tested in Liver-Impaired patients
Knowledge-focused Recruiting nowThis early-stage study tests how a single dose of the experimental hepatitis B drug pevifoscorvir sodium moves through the body in people with moderate liver impairment compared to healthy volunteers. The goal is to see if liver problems affect drug levels and safety. 16 adults a…
Phase: PHASE1 • Sponsor: Aligos Therapeutics • Aim: Knowledge-focused
Last updated May 26, 2026 05:55 UTC